Genmab Current Ratio 2019-2021 | GMAB

Current and historical current ratio for Genmab (GMAB) from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Genmab current ratio for the three months ending June 30, 2021 was 15.03.
Genmab Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $3.29B $0.22B 15.03
2021-03-31 $3.23B $0.21B 15.42
2020-12-31 $2.88B $0.19B 15.00
2020-09-30 $3.06B $0.36B 8.64
2020-06-30 $2.83B $0.30B 9.53
2020-03-31 $2.08B $0.11B 19.04
2019-12-31 $2.09B $0.14B 14.88
2019-09-30 $1.83B $0.10B 18.72
2019-06-30 $1.18B $0.08B 14.89
2019-03-31 $0.00B 0.00
2018-12-31 $1.18B $0.07B 16.77
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $28.926B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71